Paul Shaw

Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology

Richard Phillips, Bristi Basu, Zohra Butt, Mounia Beloueche et autres

gb, de (code pays fourni par la source)

Transforming the lung cancer diagnostic pathway with liquid biopsy: Early genomic results from the QuicDNA biomarker study in wales

Rachel Dodds, Rhian White, Siân Morgan, R. G. Adams et autres

gb (code pays fourni par la source)

P4.14C.08 HIT-MESO: Hemithoracic Irradiation with Proton Therapy in Malignant Pleural Mesothelioma. UK National Proton Radiotherapy Study

Crispin T. Hiley, Andre F. Gosling, Kimberley Durno, Pip Patrick et autres

in, gb (code pays fourni par la source)

Olaparib, AZD1390, ceralasertib, saruparib and consolidation durvalumab (CONCORDE) phase Ib platform study of novel DNA damage response inhibitor (DDRi) agents in combination with radiotherapy in non-small cell lung cancer (NSCLC).

Alastair Greystoke, Jamie B. Oughton, Sarah Brown, Karl T. Butterworth et autres

gb (code pays fourni par la source)

1232: Modern era radical radiotherapy toxicity: a preliminary CONCORDE analysis of the calibration arm

Ashley Horne, Sarah Brown, Alexandra Gilbert, Vicky M. Coyle et autres

204 REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm design

Ehsan Ghorani, Matteo Quartagno, Fiona Blackhall, Mary O’Brien et autres

gb (code pays fourni par la source)

78 Clinical outcomes in patients with unresectable stage III Non-Small Cell Lung Cancer (NSCLC) treated with durvalumab after chemoradiation in the United Kingdom: CODAK real-world study (NCT04667312)

K. Franks, Daniel Smith, Paul Shaw, Banna Giuseppe Luigi et autres

gb (code pays fourni par la source)

80 A single-centre experience of adjuvant Durvalumab in patients with Non-small cell lung cancer (NSCLC) treated with radical concurrent chemo-radiotherapy

Ali Hussnain, Mick Button, Najmus Sahar Iqbal, Ceri Powell et autres

gb (code pays fourni par la source)

Correction: Functional redundancy between Apc and Apc2 regulates tissue homeostasis and prevents tumorigenesis in murine mammary epithelium

Cherie Daly, Paul Shaw, Liliana Ordonez, Geraint T. Williams et autres

gb, nl (code pays fourni par la source)

CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method

Sohail Rooman Javed, Simon Lord, S. El Badri, Richard Harman et autres

gb (code pays fourni par la source)

Abstract A115: mTOR targeting in STK11 deficient Non-Small Cell Lung Cancer (NSCLC): final results, pre-clinical rationale and biomarker analysis of a phase II trial of the mTORC1/2 inhibitor vistusertib in STK11 deficient lung adenocarcinoma (NLMT B2)

Helen L. Robbins, Peter Fletcher, Joshua Savage, Manita Mehmi et autres

gb, hr (code pays fourni par la source)

P2.01-04 An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLC

A. Horne, Sarah Brown, Vicky M. Coyle, K. Franks et autres

gb, au (code pays fourni par la source)